NCT00485576View on ClinicalTrials.gov

Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

November 30, 2008

Conditions
Allergic Asthma
Interventions
DRUG

eculizumab

eculizumab 600 mg or matching placebo iv infusion.

Trial Locations (2)

L8N 3Z5

McMaster University, Hamilton

G1V 4G5

Hospital Laval, Ste-Foy

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY